Inflammatory bowel disease (IBD) poses complex issues in pregnancy, but with high-quality
care excellent pregnancy outcomes are achievable. In this article, we review the current …

Background Pregnant women with inflammatory bowel disease (IBD) are at increased risk of
adverse pregnancy outcomes. Comprehensive guidelines on medical management have …

Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-
severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile …

Objective Ustekinumab is an interleukin-12/interleukin-23 receptor antagonist licensed for
the treatment of ulcerative colitis (UC). Clinical trial data were promising; however, real …

Mood disturbances such as anxiety and depression are common in patients with
inflammatory bowel disease (IBD), and impact negatively on their quality of life and disease …

Introduction In the past 5 years, there have been several advances in the management of
inflammatory bowel disease (IBD). We aim for a new guideline to update the most recent …

Background The impact of COVID-19 on pregnant inflammatory bowel disease (IBD)
patients is currently unknown. Reconfiguration of services during the pandemic may …

Infant health outcomes are a key consideration in decisions regarding therapy for pregnant
and breastfeeding women with inflammatory bowel disease (IBD). A recent study by Kanis et …

Background Sequential drug treatment with biological agents in ulcerative colitis (UC) is
becoming increasingly complex. There are few studies comparing head-to-head outcomes …

Introduction The role of exclusive enteral nutrition (EEN) in the management of adult patients
with Crohn's disease (CD) is evolving, with non-randomised evidence suggesting a …